Diagnostics and radiology device director Alberto Gutierrez left US FDA this week after 25 years at the agency, creating another opening at the top of a diagnostics office that already has multiple vacancies in its management ranks.
Gutierrez led FDA diagnostics policy during a period of substantial reassessment and reform as the agency grappled with the rapidly evolving developments in personalized medicine, genomics and the underlying structure of the clinical laboratory market